NAFTA 2.0 and Canada’s Prescription Drug Costs

The North American Free Trade Agreement (NAFTA) is a free trade agreement between the Canada, the United States and Mexico that is currently being renegotiated.

As part of the current negotiations, the United States has tabled proposals that would lengthen periods of market exclusivity for certain brand-name drugs in Canada. If Canada were to adopt these proposals, every single Canadian would be negatively impacted by the billions of dollars in additional prescription drug costs created through delayed access to cost-savings generic and biosimilar medicines. Businesses that sponsor employee drug benefit programs, provincial and federal drug plans, and Canadians who pay for drugs out of pocket and those who make co-payments for the medicines would all be forced to shoulder the burden of the high cost of delayed competition from generic and biosimilar medicines.

The Canadian Generic Pharmaceutical Association (CGPA) is calling on the Government of Canada to hold firm against these US demands and protect Canada’s health-care system.


Canadians’ opinions on NAFTA’s impact on prescription drug costs

The Hill Times Op-Ed by Jim Keon President of CGPA

CGPA Letter to the Honourable Chrystia Freeland, Minister of Foreign Affairs

CGPA Statement on the Resumption of US-Canada Trade Talks

CGPA Statement on US-Mexico Agreement-in-Principle